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Abstract
Background: It has been suggested that a small population of cells with unique self-renewal
properties and malignant potential exists in solid tumors. Such "cancer stem cells" have been
isolated by flow cytometry, followed by xenograft studies of their tumor-initiating properties. A
frequently used sorting marker in these experiments is the cell surface protein CD133 (prominin-
1). The aim of this work was to examine the distribution of CD133 in pancreatic exocrine cancer.
Methods:  Fifty-one cases of pancreatic ductal adenocarcinomas were clinically and
histopathologically evaluated, and immunohistochemically investigated for expression of CD133,
cytokeratin 19 and chromogranin A. The results were interpreted on the background of CD133
expression in normal pancreas and other normal and malignant human tissues.
Results: CD133 positivity could not be related to a specific embryonic layer of organ origin and
was seen mainly at the apical/endoluminal surface of non-squamous, glandular epithelia and of
malignant cells in ductal arrangement. Cytoplasmic CD133 staining was observed in some non-
epithelial malignancies. In the pancreas, we found CD133 expressed on the apical membrane of
ductal cells. In a small subset of ductal cells and in cells in centroacinar position, we also observed
expression in the cytoplasm. Pancreatic ductal adenocarcinomas showed a varying degree of apical
cell surface CD133 expression, and cytoplasmic staining in a few tumor cells was noted. There was
no correlation between the level of CD133 expression and patient survival.
Conclusion: Neither in the pancreas nor in the other investigated organs can CD133 membrane
expression alone be a criterion for "stemness". However, there was an interesting difference in
subcellular localization with a minor cell population in normal and malignant pancreatic tissue
showing cytoplasmic expression. Moreover, since CD133 was expressed in shed ductal cells of
pancreatic tumors and was found on the surface of tumor cells in vessels, this molecule may have
a potential as clinical marker in patients suffering from pancreatic cancer.
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Background
Organ stem cells are slow-cycling cells with the capacity of
unlimited self-renewal, asymmetric cell division and dif-
ferentiation into mature cell types. The concept of stem
cells as a definite cell population in a supportive microen-
vironment (niche) is now widely accepted, and regarded
as the source for tissue renewal [1]. Recent studies suggest
that a small population of cells with unique self-renewal
properties and malignant potential exists in leukemia
[2,3] and in at least some solid tumors [4-6]. However,
these "cancer stem cells" are not a well-defined entity and
should still be considered a hypothesis for further explo-
ration. Whether a tumor derives from transformed organ
stem cells or whether the cancer stem cells have acquired
their self-renewal capacity during tumor development is
an open question. If the model were correct, the slow-
cycling cancer stem cells would escape current treatments
designed to kill cycling cells and should be the preferred
target population for new therapies [7-10].
In the adult pancreas, a clear identification of stem cells
has so far not been achieved (reviewed in [11-13]). Due to
the microanatomy of this organ with exocrine and endo-
crine components intimately connected and its embry-
onic origin from two separate evaginations of the
primitive gut epithelium, potential stem cell markers are
not straightforward to predict from knowledge about pan-
creatic development. Stem cells of the pancreas therefore
remain to be unequivocally identified, even though the
research activity is high because of the urgent need of a
resource of beta-cells for transplantation in patients suf-
fering from insulin-dependent diabetes mellitus. Candi-
dates for pancreatic stem cells have been suggested to
reside both in the ductal epithelium, in the islets and
among the acinar cells [14-16]. Further controversies arise
from studies that have reported self-renewal of beta-cells
[17,18], transdifferentiation of acinar cells [19] and cellu-
lar contributions from the bone marrow [20]. Li and co-
workers recently described a subpopulation of tumor cells
from pancreatic cancer tissue with increased tumorigenic
potential in mice [21]. However, studies of potential can-
cer stem cells from human solid tumors have some imma-
nent problems due to the necessity of tissue processing
before cell sorting and of transfer to another species for
functional testing.
Expression of the surface protein CD133 (also known as
AC133 and prominin-1) is one criterion which has been
used in the identification of putative cancer stem cells
from solid tumors (brain: [5,6], lung: [22], skin
melanoma: [23], prostate: [24], kidney: [25], colon:
[26,27], liver: [28]). CD133 is expressed in a variety of cell
lines, developing epithelia and differentiated cells in
mammals and metazoans (reviewed in [29,30]). It was
originally regarded as a marker for stem and progenitor
cells of the hematopoietic system [31,32]. The human
CD133 protein is encoded by the PROM1 gene on chro-
mosome 4p15 and codes for a five-transmembrane glyco-
protein [33,34]. Structurally, it consists of an N-terminus
on the extracellular side, two short intracellular loops, two
large extra cellular loops containing eight N-linked glyco-
sylation sites, and an intracellular C-terminus [33,35].
CD133 localizes to plasma membrane protrusions at the
apical surface of cells, reflecting a polarized cell structure
[35-39]. The function of the protein is unknown. Exami-
nation of a family with autosomal recessive retinal degen-
eration revealed a PROM1  mutation resulting in a
truncated form of CD133, which was not transported to
the cell surface [40].
CD133 mRNA has been shown to be upregulated in shed
ductal cells from pancreatic cancer patients [41] and in
two pancreatic cancer cell lines [42]. The protein expres-
sion pattern of CD133 has not been thoroughly examined
in the normal pancreas or pancreatic malignancies. By
using immunohistochemical methods, we sought to per-
form a characterization of the tissue distribution of this
protein in formalin-fixed, paraffin-embedded human tis-
sue, with particular emphasis on the pancreas. We found
that the amount of cancer cells expressing CD133 on their
surface is far too high to be restricted to a cancer stem cell
population. However, we noted a subpopulation with
predominantly cytoplasmic positivity, which stained sim-
ilarly to some single cells in the normal duct epithelium
and to cells in centroacinar position. These are suggested
sites for stem cells of the adult pancreas [15,16] and for
the origin of pancreatic intraepithelial neoplasia [43,44],
a precursor lesion of infiltrative ductal adenocarcinomas.
Methods
Tissue specimens
Tissue specimens from normal human organs and
tumors, including 51 pancreatic adenocarcinomas
resected in the period 1997–2004, were retrieved from the
archives of the Department of Pathology, the Gade Insti-
tute, Haukeland University Hospital. A pathologist (H.I.)
reviewed the slides to ensure that the cases were consistent
with pancreatic ductal adenocarcinoma according to the
WHO classification [45]. Clinical records and radiological
reports were reviewed by a surgeon (D.H.). The pancreatic
tumor samples are an extended series of that described by
Immervoll et al. [46]. The study was approved by the
Regional Ethics Committee and performed according to
the Helsinki Declaration.
Tissue micro-arrays
For construction of tissue micro-arrays (TMA) of forma-
lin-fixed, paraffin-embedded pancreatic tumors, areas
containing cancerous and normal tissue were identified in
hematoxylin-eosin (H&E) stained slides. The TMAs wereBMC Cancer 2008, 8:48 http://www.biomedcentral.com/1471-2407/8/48
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manually constructed using a commercial tissue micro-
arrayer (Beecher Instruments, Silver Spring, MD). The
TMA blocks consisted of four columns of cylindrical
tumor tissue fragments and one column of a cylindrical
fragment of tumor-free pancreatic tissue for each case. The
cylindrical fragments were 1 mm in diameter and two
punch-outs were put on top of each other to obtain a
height of 4 mm. Tissue fragments were melted into the
acceptor paraffin block by heating the block for 30 min-
utes at 39°C.
Immunohistochemistry
The primary antibodies employed are listed in Table 1.
Immunohistochemical staining was done on 3–4 μm-sec-
tions from formalin-fixed, paraffin-embedded tissues,
placed on coated glass slides, and dried at 60–70°C for 30
min. For CD133, retrieval methods, buffer solutions,
incubation time and concentrations of the primary anti-
bodies were varied to find the optimal procedure. As anti-
body detection method, two polymer-based systems and
one streptavidin-biotin system were tested (EnVision and
LSAB, both from Dako, Glostrup, Denmark; MACH3 Pol-
ymer Detection Kit from Biocare Medical, Concord, CA).
For double-labeling with cytokeratin 19 (CK19) or
chromogranin A, standard methods employed in routine
diagnostic service were used with antibody concentrations
adjusted (Table 1).
The CD133 detection method that we judged to be most
sensitive and specific was the following: Antigen retrieval
was performed by incubation in a pressurized heating
chamber (Pascal, Dako) at 120°C for 1 min in Tris-EDTA
buffer (pH 9). The slides were then cooled in running tap
water and incubated with primary antibody (clone
AC133; Miltenyi, Bergisch Gladbach, Germany) diluted
1:25 in an antibody diluent with reduced salt concentra-
tion (25 mM Tris, 75 mM NaCl, 1% BSA, 0.01% methi-
olate, 0.05% Tween 20; pH 7.4) for 60 min. This and all
subsequent steps were carried out at room temperature.
Next, blocking for unspecific peroxidase activity was done
by 3% H202 treatment for 5 min. Primary antibody detec-
tion was performed, in accordance with the manufac-
turer's instructions, with the MACH3 mouse probe
(Biocare Medical) for 20 min, followed by MACH3 HRP
polymer (Biocare Medical) for 20 min, and the signal was
developed with diamino-benzidine DAB+ (Dako) for 5
minutes. Between each step, there were two washing steps
for 1 min each on a rocking platform in washing buffer
(50 mM Tris, 150 mM NaCl, 0.05% Tween 20; pH 7.5).
Finally, the slides were counter-stained with hematoxylin
for 1 min, dehydrated in alcohol solutions and xylene,
and mounted in Entellan (Merck, Darmstadt, Germany).
Assessment of immunohistochemical staining
The quality of staining was judged in control material
from different organs, according to the data in the litera-
ture about gene/protein expression of CD133 in various
tissue types [33,35,37,47]. TMA slides containing pancre-
atic ductal adenocarcinomas were scored independently
by two of the authors (H.I., A.M.) as negative (0), weakly
positive (1) or strongly positive (2) for CD133 expression.
Cases with different scoring were discussed to reach a con-
sensus. As validation for TMA interpretation, whole sec-
tions from the border between adenocarcinoma and
nearby normal pancreatic tissue were made from ten of
the cases included in the TMA block, and treated and eval-
uated in the same way as the TMA slides. Parallels were
stained with H&E for control of the tissue quality. The
whole sections were also screened at 1000× magnifica-
tion, looking for features such as nuclear/cytoplasmic
staining, expression in vessels etc.
Western blot
Snap-frozen tissue from patient biopsies was crushed in
liquid nitrogen, dissolved in lysis buffer (20 mM MOPS, 5
mM EDTA, 2 mM EGTA, 30 mM NaF, 0.5% Triton X, 40
mM b-glycerophosphate, 20 mM Na-pyrophosphate, 1
mM Na-orthovanadate, 3 mM benzamidine, 5 μM Pepsta-
tin, 10 μM Leupeptin, 1 mM PMSF; pH 7.2), homoge-
nized for 15 s using a Polytron Homogenizer (Brinkman,
Westbury, NY) and spun down at 20000 g for 30 min.
Twenty  μg protein from the resulting supernatant was
applied in each well and separated by SDS-PAGE using
NuPage pre-cast gels (Invitrogen, Carlsbad, CA). After
transfer to a nitrocellulose membrane for 1 h at 30 V and
subsequent treatment with blocking solution (TBS with
0.1% Tween and 5% milk powder) for 30 min at room
temperature, the membrane was incubated overnight at
4°C in blocking solution containing anti-CD133 mouse
monoclonal antibody (clone AC133 or AC141, Miltenyi)
Table 1: Primary antibodies used for immunohistochemistry
Antigen Antibody subtype Dilution Product no. Manufacturer
CD133/1 (clone AC133) Mouse monoclonal 1:25 130-090-422 Miltenyi Biotec, Bergisch Gladbach, Germany
CD133/2 (clone AC141) Mouse monoclonal 1:25 130-090-423 Miltenyi Biotec, Bergisch Gladbach, Germany
CD133 (K-18) Goat polyclonal 1:50 sc-23797 Santa Cruz Biotechnology, Santa Cruz, CA
Cytokeratin 19 Mouse monoclonal 1:150 M0888 Dako, Glostrup, Denmark
Chromogranin A Rabbit polyclonal 1:3000 A0430 Dako, Glostrup, DenmarkBMC Cancer 2008, 8:48 http://www.biomedcentral.com/1471-2407/8/48
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diluted 1:100. The primary antibodies were detected using
a horseradish peroxidase-conjugated goat anti-rabbit/
mouse secondary antibody diluted 1:20,000 (Immu-
notech, Fullerton, CA). The Western blot was developed
using Supersignal West Pico Chemiluminescent Substrate
(Pierce Biotechnology, Rockford, IL) and detected with a
Fuji LAS 3000 Imager (Fuji Photo Film Co, Tokyo, Japan).
Statistics
The statistical analyses were performed using the software
package Statistica 4.1 (StatSoft Inc., Tulsa, OK). The Prod-
uct-limit (Kaplan-Meier) Analysis Module was used for
comparing survival between multiple groups. Survival
times versus cumulative proportion surviving, according
to breakdown by staining intensity groups 0, 1 and 2, were
plotted.
Results
Specificity of CD133 staining
We tested three different antibodies against CD133 (Table
1) on formalin-fixed, paraffin-embedded human retina, a
tissue with known CD133 expression [40]. The mono-
clonal antibody AC133 gave the most sensitive results
with the lowest background staining (Figure 1, see also
Materials and Methods). There was abundant cytoplasmic
and membrane positivity in the apical part of the rod and
cone cells and less intense staining basal to their nuclei,
possibly representing the apical end of neighboring cells.
Staining with the polyclonal antibody K-18 was weaker
and more difficult to separate from the background,
whereas the monoclonal antibody AC141, recognizing a
different CD133 epitope than AC133, did not show a pos-
itive reaction on retinal tissue (not shown). The specificity
of the AC133 antibody was confirmed by Western blot-
ting of protein-extracts from normal pancreas and pancre-
atic ductal adenocarcinoma (Figure 1C).
CD133 expression in normal and malignant tissues
We examined CD133 expression in endodermal, meso-
dermal and neuroectodermal organs of adult humans. In
non-squamous, glandular epithelia, we observed an api-
cal membrane staining of cells arranged in ductal struc-
tures (Figure 2). Squamous epithelia of the skin, adult
non-epithelial tissues (fatty tissue, fibrous tissue, blood
and lymphatic vessels, lymph nodes) and neural tissues
(brain and peripheral nerves) were all negative (Figure 2
and not shown). In the stomach, duodenum and colon
(Figure 2A, 2B, 3A), cells at the basis of the crypts – where
stem cells are likely to reside – expressed CD133 at their
apical/endoluminal surface. The staining pattern of the
epithelia may reflect a particular stage in maturation as
the more differentiated cell populations in the upper part
of the mucous membranes were negative. In tubularly
arranged epithelia of the liver, pancreas, salivary and
mammary gland, CD133 expression started at the proxi-
Control of the specificity of CD133 staining Figure 1
Control of the specificity of CD133 staining. A) A section of 
retina showing strong membranous and cytoplasmic staining 
concentrated in the apical part of both cone and rod cells. 
Weak positivity is noted in a layer basal to the cone and rod 
nuclei. B) A parallel retina section processed similarly to A, 
except from the addition of primary antibody. The cell layers 
are rods and cones (1), horizontal, bipolar and amacrine cells 
(2) and ganglion cells (3). A, B = ×400, scale bar = 100 μm. 
C) Western blot stained with the two antibodies AC141 
(lanes 1 and 2) and AC133 (lanes 3 and 4). Only AC133 rec-
ognized the expected band of around 117 kDa. T and N 
denote protein extracts from a pancreatic ductal adenocarci-
noma and from normal pancreas, respectively. The band sizes 
(kDa) of the molecular weight standard in lane 5 are listed to 
the right.
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CD133 expression in endodermal, mesodermal and neuroectodermal tissues Figure 2
CD133 expression in endodermal, mesodermal and neuroectodermal tissues. Endodermal: A) stomach, B) duodenum, C) gall 
bladder, D) liver, E) pancreas, F) salivary gland. Mesodermal: G) kidney, H) endometrium in secretory state, I) lymphatic tis-
sue (tonsil) with a germinal center. Neuroectodermal: J) brain (cortex cerebri), K) skin, L) mammary gland. Retina staining 
(neuroectodermal) is shown in Figure 1A and colon staining (endodermal) in Figure 3A. Note the apical/endoluminal mem-
brane staining in glandular epithelia in general. In the stomach (A), duodenum (B) and colon (3A), CD133 expression is 
restricted to cells at the basal part of the mucous membrane. In the gall bladder (C), biliary ducts of the liver (D), endometrium 
(H) and mammary gland (L), there is homogenous apical membrane staining. In the pancreas (E) and the salivary gland (F), 
homogenous endoluminal staining of the smallest ductal structures is present. In the kidney (G), all cells of the Bowman's cap-
sule seem to express CD133 in the cytoplasm and membrane, whereas apical membrane staining is present in some of the duct 
cells (asterisk). No staining was detected in tonsils (I), lymph nodes (not shown), cortex cerebri (J) or skin (K). Weak color in 
the cytoplasm of basal cells in the skin is supranuclear melanin pigment. A-C, I-L = ×200, scale bar in A = 100 μm. D-H = ×400, 
scale bar in A = 50 μm.
A C
Endodermal
D E F
Mesodermal
G H I
Neuroectodermal
J K L
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mal end of the lumen and was maintained with increasing
diameter of the duct (Figure 2D–2F, 2L).
We also stained tissues from a set of human malignancies:
colon carcinoma, carcinoma of the mammary gland,
glioblastoma multiforme (GBM), chronic myelogenous
leukemia, gastrointestinal stromal tumor (GIST) and
three types of testicular tumors (Figure 3). In malignant
tissues, we observed two distinct staining patterns: There
was apical/endoluminal membrane staining, opposite to
the basal membrane, in the malignant glandular epithe-
lia, whereas the non-epithelial tumors mainly exhibited
perinuclear/cytoplasmic positivity. Moreover, in the infil-
trating ductal carcinoma of the mammary gland (Figure
3F), distinct cytoplasmic globules expressing CD133 were
seen where cytoplasmic lumina had been formed or
where mucus had been retained in the cytoplasm.
In the normal tissues studied in Figure 2 as well as in the
epithelial tumors of Figure 3, cytoplasmic CD133 staining
was observed only in some rare, single cells. This contrasts
to the staining pattern of the non-epithelial tumors (GBM,
GIST, chronic myelogenous leukemia, intratubular germ
cell neoplasia and seminoma) shown in Figure 3. Cyto-
plasmic CD133 expression appeared most abundant in
the GIST (Figure 3H), and a series of 27 such tumors were
examined, 22 (81%) being positive. There was varying
CD133 intensity, not related to morphologic variations
(not shown). In GBM and chronic myelogenous leuke-
mia, only a few cells with perinuclear cytoplasmic staining
were noted (Figure 3G, 3I). The same cytoplasmic staining
but in more cells, was seen in intratubular germ cell neo-
plasia and seminoma (Figure 3J, 3K). The embryonal car-
cinoma (Figure 3L) did show strong endoluminal cell
membrane staining whenever a lumen was seen, and also
weak cytoplasmic staining.
The overall impression from the normal and malignant
tissues depicted in Figures 2 and 3 is that CD133 positivity
is related to tissue architecture. The protein is expressed
apically in the membrane of epithelial cells when a lumen
has been formed and in the cytoplasm of solidly arranged
malignant tissues of non-epithelial origin. Staining was
not restricted to organs arising from a particular embry-
onic layer.
Expression in normal pancreatic tissue
We then focused our study on pancreatic CD133 expres-
sion. In normal pancreas, CD133-positive cells were seen
in the center of the acini whenever a small lumen was
present (Figure 4). The positivity continued in the follow-
ing ducts and, with variable and decreasing intensity, into
the larger ducts. Cells expressing CD133 on their apical/
endoluminal surface showed wide co-expression of CK19
in their cytoplasm. CK19 staining apparently followed a
gradient with strongest intensity in the larger ducts, fading
towards the periphery and negative in the tiniest ducts or
centroacinar cells which still showed some CD133 expres-
sion (Figure 4B). No co-expression of CD133 and chrom-
ogranin A was observed (Figure 4C). Although staining
was seen at the apical membrane in the vast majority of
cells, single cells in some ducts showed strong cytoplasmic
staining (Figure 4D). In the acini (Figure 4E), a few cells
located near the luminal surface showed strong CD133
expression suggesting cytoplasmic staining in the centro-
acinar cells, but these are difficult to separate from acinar
cells by light microscopy only. Staining was never seen in
the islets of Langerhans (Figure 4A, 4F). To verify that the
epitope(s) recognized by the antibody clone AC133 were
not influenced by the processes of formalin fixation,
dehydration and antigen retrieval, we stained cryosections
of normal human pancreas. The staining pattern was the
same as described above, with apical/endoluminal
CD133 positivity in the proximal ducts and completely
negative islets (not shown).
In fetal pancreatic tissue (Figure 4G, 4H), the ductal cells
and cells of the center of small acini showed CD133 pos-
itivity but the staining appeared less distinct than in tissue
from adult pancreas. Tissue morphology and staining pat-
tern were strikingly similar in normal fetal pancreas and
pancreatic tissue with fibrosis and atrophy of the exocrine
tissue in adults (Figure 4I). In fetal tissue the chrom-
ogranin A-positive endocrine cells were intermingled
between acinar and duct cells and the endocrine and exo-
crine cells were not as clearly separated as in the adult pan-
creas (Figure 4G, 4H). In the normal pancreas, the
antibody K-18 (Table 1) stained the same cells as AC133,
but more weakly (results not shown).
Expression in pancreatic ductal adenocarcinomas
CD133 expression was evaluated in a series of 51 pancre-
atic ductal adenocarcinomas in TMA blocks. Forty-one
cases (80%) were positive, and expression was mainly
seen in the apical/endoluminal cell surface in malignant
ductal structures (Figure 5A–D). In the positive cases,
expression area and intensity varied along with the mor-
phological heterogeneity of the tumor. The CD133
expression pattern in colon and mammary gland adeno-
carcinomas could indicate higher expression in lower
grade tumors. This was not true for pancreatic adenocarci-
nomas in our series. Some well-differentiated/low-grade
tumors with mucous production had low CD133 expres-
sion (Figure 5B) and some low-differentiated/high-grade
tumors still formed tubuli with abundant endoluminal
CD133 expression (Figure 5C). Moreover, there was no
significant correlation of CD133 expression with survival,
TNM tumor stage or differentiation grade in our series
(Figure 6 and not shown). Interestingly, debris in small
and dilated ducts lined by malignant epithelium wasBMC Cancer 2008, 8:48 http://www.biomedcentral.com/1471-2407/8/48
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CD133 expression in normal and neoplastic tissues Figure 3
CD133 expression in normal and neoplastic tissues. Epithelial tissues and tumors: A) normal colon mucosa, B) colon ade-
noma, C) colon adenocarcinoma, D) normal mammary gland, E) mammary adenoma, F) mammary carcinoma. Non-epithelial 
malignant tissues: G) brain glioblastoma multiforme, H) gastrointestinal stromal tumor, I) myelogenous leukemia soft tissue 
infiltrate. Germ cell neoplasias of the testis: J) Intratubular germ cell neoplasia, K) seminoma, L) embryonal carcinoma. Note 
the apical/endoluminal membrane staining in epithelial tissues (A, D) and in neoplasias with tubule-forming tumor cells (B, C, E, 
F, L). In solid tumors without tubular structures there is perinuclear or diffuse cytoplasmic staining (G-K). A = ×200, scale bar 
= 100 μm. B, C = ×100, scale bar in A = 200 μm. D-F, H, J-L = ×400, scale bar in A = 50 μm. G, I = ×1000, scale bar in A = 20 
μm.
A B C
Epithelial
D E F
Germ cell-derived
G H I
Non-epithelial
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strongly stained in positive cases (Figure 5A) and also
found in cases otherwise weakly positive (Figure 5B).
Cytoplasmic CD133 staining was seen in less than 1% of
the malignant epithelial cells (Figure 5E, 5F) as estimated
from the ten cases where a whole section of tumor tissue
was available for examination. In a well-differentiated
pancreatic cancer double-stained with CK19 (Figure 5G),
we could demonstrate a similar staining pattern as seen in
the normal pancreas in areas where acini and ducts con-
nect: Cytoplasmic CK19 was co-expressed with membra-
nous CD133 in apical/endoluminal cells lining the ductal
lumen whereas some cells expressed cytoplasmic CD133,
but not CK19, at the site of solid growth.
In papillary arranged tumor cell groups that did not have
a central lumen, CD133 staining was turned "inside-out"
(Figure 5H). This phenomenon was seen especially in
cancer cell groups inside vessels (Figure 5I) and in addi-
tion on the entire surface of shed single cells, lying in
malignant ducts (Figure 5B, 5H). In investigated lymph
node metastases, malignant cells did mirror the focal, api-
cal/endoluminal membrane staining of CD133 in the pri-
mary tumors (Figure 5J). The phenomenon of outer
surface staining of tumor cells infiltrating vessels was also
observed in lymph nodes (Figure 5J).
Discussion
We have examined CD133 expression in normal and
malignant human tissues with special emphasis on pan-
creas and pancreatic ductal adenocarcinomas. In the nor-
mal tissues, expression was seen mainly at the apical/
endoluminal surface of non-squamous, glandular epithe-
lia and could not be related to a specific embryonic layer
CD133 expression in adult and fetal pancreas Figure 4
CD133 expression in adult and fetal pancreas. A-F) Normal adult pancreas. Note the apical/endoluminal staining of the ducts 
and that the islets of Langerhans (asterisks in A) are negative. See also Figure 2E. B) Double staining with CD133 (brown) and 
cytokeratin 19 (red) showing abundant co-expression of the two markers. The insert is a higher magnification showing CD133-
positive, CK19-negative cells in the region connecting ducts and acini (arrow). C) Double staining with CD133 (brown) and 
chromogranin A (red). No co-expression was detected. D) A duct with a single cell exhibiting cytoplasmic CD133 positivity 
(arrow). E) Acini with apical/endoluminal expression whenever a visible lumen is present. The arrow points to a cell in centro-
acinar position, apparently having cytoplasmic expression. F) A CD133-negative islet. G, H) Fetal pancreas at gestational week 
18, low and high magnification. Staining as in C. I) Chronic inflammation and atrophic exocrine tissue. Staining as in C. Note the 
similarity to G in general architecture and the difference in distribution of chromogranin A-positive endocrine cells. A-C = 
×400, scale bar in A = 50 μm. D-F, H = ×1000, scale bar in A = 20 μm. G, I = ×200, scale bar in A = 100 μm.
A B C
D E F
G H IBMC Cancer 2008, 8:48 http://www.biomedcentral.com/1471-2407/8/48
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CD133 expression in pancreatic ductal adenocarcinomas Figure 5
CD133 expression in pancreatic ductal adenocarcinomas. A-D) Variable expression in carcinomas of high (A, B) and low (C, 
D) differentiation grade. The insert in A is a high magnification of a cancerous duct with intense CD133 positivity in amor-
phous, intraductal material. E, F) Rare, single tumor cells with cytoplasmic staining (arrows). G) CK19-CD133 double staining 
of a malignant duct. Note cytoplasmic CD133 expression (brown) in a CK19-negative cell group (arrow) and co-expression of 
both markers in cells surrounding the lumen (asterisk). H-J) Staining (asterisks) at the apical/endoluminal membrane surface 
and surface of papillary arranged tumor cell clusters in a malignant duct (H), in a vessel of a primary tumor (I) and in a vessel of 
a lymph node metastasis (J). A-D = ×200, scale bar in A = 100 μm. E-G = ×1000, scale bar in A = 20 μm. H, J = ×400, scale bar 
in A = 50 μm. I = ×630, scale bar in A = 32 μm.
I J
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of organ origin. A similar staining pattern was seen in
malignant epithelial tissues. However, in some non-epi-
thelial malignancies cytoplasmic positivity was observed
either diffusely in the cytoplasm of the majority of tumor
cells (GISTs) or as discrete, perinuclear dots in a few
tumor cells (GBM, myelogenous leukemia). Such perinu-
clear CD133 staining in a few cells have also been
reported in the sub-ependymal zone of fetal human brain
[48]. In germinal cell-derived tumors, staining varied
according to the architecture. In summary, CD133 was
located at the apical/endoluminal surface of cells forming
lumina and in the cytoplasm of cells when they exhibited
solid growth.
Pancreatic expression of CD133
In the normal pancreas, CD133 is expressed at the apical/
endoluminal surface of ductal cells. The expression
appeared more pronounced towards the acini than
towards the larger ducts. CD133 and CK19 (a marker for
ductal cells) were generally co-expressed in the fully differ-
entiated ductal epithelium. CD133-positive and CK19-
negative cells were present in the region connecting the
smallest ducts and secretory acinar cells. In this region
there were some single cells in a centroacinar position
with mainly cytoplasmic CD133-staining. Cytoplasmic
expression was also observed in single ductal cells. They
did not differ in their morphology or position from neigh-
boring cells. We therefore conclude that they do not cor-
respond to the so-called "helle Zellen" [49], members of
the diffuse neuroendocrine system of the pancreas.
Areas where epithelia of divergent differentiation coincide
have been proposed as locations (niches) for organ-spe-
cific stem cells in intestine and liver [50-52]. Recently the
centroacinar cells of the pancreas have come into focus as
a probable cell of origin in pancreatic intraepithelial neo-
plasia (PanIN), thereby also becoming candidates for the
progenitors of ductal adenocarcinomas [43]. We note that
the centroacinar cells may appear to be demarcated by
cytoplasmic CD133 staining and CK19 negativity. It is
therefore tempting to speculate that these cells form a sub-
population with a specific role in pancreatic exocrine tis-
sue.
Both in the normal pancreas and in the ductal adenocar-
cinomas, CD133 is expressed in far too many cells to be a
specific (cancer) stem cell marker. Notably, a high per-
centage of CD133-expressing cells (up to 24%) was
reported also in colon cancer [26], but there were no data
about subcellular localization. We suggest that CD133-
expressing cells in the pancreas, as demonstrated by the
AC133 antibody, include at least two subpopulations. The
main population expresses CD133 at the cell surface and
represents a particular stage in cell differentiation con-
nected to the formation of lumina and ducts. The minor
population has mainly cytoplasmic staining and repre-
Cumulative proportion survival (Kaplan-Meier) plot for 51 pancreatic adenocarcinomas according to breakdown by CD133  expression (negative = 0, weakly positive = 1, strongly positive = 2) Figure 6
Cumulative proportion survival (Kaplan-Meier) plot for 51 pancreatic adenocarcinomas according to breakdown by CD133 
expression (negative = 0, weakly positive = 1, strongly positive = 2). Median survival time was 16, 9 and 15 months for groups 
0, 1 and 2, respectively. The observed survival times are indicated by circles (complete) or crosses (censored observations).
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sents less than 1% of epithelial cells, both in normal pan-
creas and in the ductal adenocarcinomas. If the
population with cytoplasmic CD133 expression could be
shown to serve a role as stem cells in the normal tissue, it
would become an interesting candidate for the transfor-
mation to tumor-initiating cells in pancreatic cancer.
CD133 as a potential clinical marker in pancreatic cancer
Pancreatic ductal adenocarcinoma is usually detected at
an advanced stage and is one of the human cancers with
the worst prognosis. Earlier detection will probably be
essential for improving patient survival. Biochemical or
molecular analysis of pancreatic juice could be one option
for increasing the likelihood of early diagnosis. Yoshida et
al. [41] investigated purified ductal cells from the pancre-
atic juice of healthy individuals and cancer patients, and
demonstrated upregulation of CD133 mRNA in some
cases. We here show expression of CD133 protein in the
epithelium lining the ducts of both normal and cancerous
exocrine tissue. We also observed shed, CD133-expressing
tumor cells and apparently non-cellular, CD133-positive
material in the malignant ducts. Thus, a quantitative anal-
ysis of CD133 in pancreatic juice from suspected cancer
patients might be of interest, in particular with regard to
whether it could aid the discrimination between chronic
inflammation and malignancy.
Intriguingly, we noted CD133 expression on the outer
surface of tumor cell groups in small lymphatic or blood
vessels. CD133 has been detected on extra-cellular mem-
brane particles isolated from neuroepithelial and epithe-
lial cells in various body fluids [53]. Moreover, in a series
of patients suffering from colon cancer, Lin et al. [54] dis-
covered that a high level of CD133 mRNA in blood pre-
dicted disease recurrence. Their interpretation was that
bone marrow-derived, endothelial progenitor cells and
not cancer stem cells were the source of the elevated
CD133 mRNA levels. Nevertheless, CD133 mRNA and/or
protein levels in blood could be of predictive or even diag-
nostic value. Thus, the results of Marzesco et al. [53] and
Lin et al. [54] along with our own observations warrant
further studies of CD133 mRNA and/or protein in blood
samples from pancreatic cancer patients.
CD133 expression and implications for cell sorting
According to the literature, the distribution of CD133
mRNA and results from immunohistochemistry using
AC133 as primary antibody is not completely concordant
[38]. Moreover, many tissues where we observed positive
staining have previously been reported negative for
AC133 by immunohistochemistry [33,38]. There are
many explanations for the observed discrepancies. Our
protocol of immunostaining on formalin-fixed, paraffin-
embedded tissue involves a relatively high concentration
of the AC133 antibody and a sensitive detection system,
indicating that there may be problems in epitope retrieval
or antibody sensitivity in fixed material. In addition, the
antibody clone AC133 recognizes an epitope containing a
potential glycosylation site [37], which suggests that the
non-glycosylated form may escape detection. There are
also a multitude of CD133 mRNA splice variants [55] and
neither AC133 nor other antibodies can be expected to
cover all protein variants that may be produced by the dif-
ferent mRNAs.
Several seminal studies [5,6,26,27,31,56,57] have used
AC133 as a tool in fluorescent-activated cell sorting
(FACS), isolating normal or malignant cells with stem
cell-like properties. FACS requires tissue dissociation. The
mechanical and enzymatic procedures necessary to make
single-cell suspensions disrupt the cellular microenviron-
ment and can be expected to alter the expression of both
extra- and intracellular proteins, thereby influencing the
selection of the cell population to be used in subsequent
transplantation experiments. Despite the central role of
CD133 as a marker for selecting postulated cancer stem
cells, it is not known how this protein is affected by the
procedures used for tissue dissociation and this needs to
be addressed experimentally.
The data acquired by CD133-positive cells sorted from
single-cell suspensions derived from solid tissues must
therefore be interpreted with caution, especially since the
physiological function of the CD133 protein may be con-
nected to cell polarity [58] and to cell orientation in tis-
sues [35]. Such a role would be in accordance with the
apical/endoluminal staining pattern that we report in this
paper. How the cell populations that we detect by immu-
nohistochemistry on formalin-fixed, paraffin-embedded
tissue relate to those sorted by FACS using the same pri-
mary antibody, remains to be studied. One possibility is
that the cells with abundant cytoplasmic expression are
those with the highest level of CD133 protein in the mem-
brane.
The function of CD133
The physiological role of CD133 is elusive. As discussed
above, studies are complicated by the occurrence of many
mRNA splice variants and possibly also by a changing gly-
cosylation status of the protein. There are several commer-
cially available antibodies towards human CD133,
yielding overlapping but different staining patterns (own
unpublished data). Moreover, the protein is present at dif-
ferent locations in the cell (cytoplasm or membrane),
which in turn may reflect specific cellular functions. Taken
together, our data on CD133 expression in the pancreas as
well as in other organs indicate that the protein relates to
tissue architecture, apical/endoluminal membranous
staining of CD133 being a characteristic of well-oriented,
polarized and differentiated cells of glandular epithelia.BMC Cancer 2008, 8:48 http://www.biomedcentral.com/1471-2407/8/48
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As mentioned, CD133 has been implicated in cell polar-
ity, which is required for cell movement [58,59]. The latter
is crucial for processes such as chemotaxis, embryonic
development, invasive growth and metastasis, but not in
itself regarded a stem cell property. However, cell polarity
is also important for asymmetric cell division, an inevita-
ble characteristic of stem cells [60]. Kosodo et al. [61]
described the asymmetric distribution of a minute frag-
ment of the apical plasma membrane expressing CD133
to the daughter cells in asymmetric neurogenic divisions
during central nervous system development. Dubreuil et
al. [62] showed CD133 expression in apical midbodies
during symmetric cell divisions of neuroepithelial cells
and the release of these apical midbodies in the neural
tube fluid. Both studies link the plasma membrane
domain in which CD133 is included, to the type of cell
division. The existence of CD133-positive, non-cellular
and therefore probably plasma membrane fragments in
our series of pancreatic ductal adenocarcinomas could be
a result of CD133 release during proliferative symmetric
cell divisions, the main type of cell divisions responsible
for tumor growth. It is a further argument for investigating
pancreatic juice and blood of pancreatic cancer patients
for CD133 at the protein level.
A stem cell population is characterized by the lack of dif-
ferentiation markers and the ability to undergo multi-lin-
eage differentiation. For the cancer stem cell hypothesis,
however, xenograft tumor models have been an essential
experimental approach. In several such studies, CD133
was hailed as a cancer stem cell marker [6,22-28]. It is,
however, doubtful that CD133 expression in tumor-initi-
ating cells is an absolute necessity in xenograft models, as
it recently was shown that human brain tumors can be
transplanted from CD133-negative cancer cells [63,64].
Results from xenograft experimental models have there-
fore to be carefully interpreted [48]. Tumor initiation at
other places than the primary organ of origin and in a dif-
ferent species is probably a fine-tuned process where the
microenvironment and immunity is of major importance.
It will be essential to uncover the physiological role of
CD133 for determining whether it is a marker for a true
cancer stem cell population or a marker for cells with
enhanced capability to proliferate in other species [65].
Conclusion
CD133 expression in the form of the epitope recognized
by the antibody AC133 was not related to a specific
embryonic layer of organ origin. The protein was found at
the apical/endoluminal surface of glandular epithelia and
of malignant cells in ductal arrangement. In pancreatic
ductal adenocarcinomas, CD133 was present in shed
tumor cells and on the surface of tumor cell groups in ves-
sels, suggesting a potential as clinical marker. Neither in
the pancreas nor in the other investigated organs can
CD133 membrane expression alone be a criterion for
"stemness".
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